Amgen is trading 3.17% up at $438.76 as biotechnology shares rally broadly on positive Moderna-Merck Phase 3 melanoma vaccine results.
- The sector ETF XBI is up 3.73% during regular trading, making industry-wide optimism the clearest explanation for Amgen’s move.
- Amgen’s recent second-quarter earnings beat and raised 2026 outlook provide supportive background, but no fresh company-specific announcement on August 19 directly explains the gain.